Skip to main content

Research Repository

See what's under the surface

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers

Abdel-Fatah, Tarek M.A.; Ali, Reem; Sadiq, Maaz; Moseley, Paul M.; Mesquita, Katia A.; Ball, Graham; Green, Andrew R.; Rakha, Emad A.; Chan, Stephen Y.T.; Madhusudan, Srinivasan

Authors

Tarek M.A. Abdel-Fatah

Reem Ali

Maaz Sadiq

Paul M. Moseley

Katia A. Mesquita

Graham Ball

Andrew R. Green

Emad A. Rakha

Stephen Y.T. Chan

Srinivasan Madhusudan



Abstract

Genomic instability could be a beneficial predictor for anthracycline or taxane chemotherapy. We interrogated 188 DNA repair genes in the METABRIC cohort (n = 1980) to identify genes that influence overall survival (OS). We then evaluated the clinicopathological significance of ERCC1 in early stage breast cancer (BC) (mRNA expression (n = 4640) and protein level, n = 1650 (test set), and n = 252 (validation)) and in locally advanced BC (LABC) (mRNA expression, test set (n = 2340) and validation (TOP clinical trial cohort, n = 120); and protein level (n = 120)). In the multivariate model, ERCC1 was independently associated with OS in the METABRIC cohort. In ER+ tumours, low ERCC1 transcript or protein level was associated with increased distant relapse risk (DRR). In ER−tumours, low ERCC1 transcript or protein level was linked to decreased DRR, especially in patients who received anthracycline chemotherapy. In LABC patients who received neoadjuvant anthracycline, low ERCC1 transcript was associated with higher pCR (pathological complete response) and decreased DRR. However, in patients with ER−tumours who received additional neoadjuvant taxane, high ERCC1 transcript was associated with a higher pCR and decreased DRR. High ERCC1 transcript was also linked to decreased DRR in ER+ LABC that received additional neoadjuvant taxane. ERCC1 based stratification is an attractive strategy for breast cancers.

Journal Article Type Article
Publication Date Aug 10, 2019
Journal Cancers
Electronic ISSN 2072-6694
Publisher MDPI
Peer Reviewed Peer Reviewed
Volume 11
Issue 8
Article Number 1149
Institution Citation Abdel-Fatah, T. M., Ali, R., Sadiq, M., Moseley, P. M., Mesquita, K. A., Ball, G., …Madhusudan, S. (2019). ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. Cancers, 11(8), doi:10.3390/cancers11081149
DOI https://doi.org/10.3390/cancers11081149
Keywords Cancer Research; Oncology
Publisher URL https://www.mdpi.com/2072-6694/11/8/1149

Files

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers (1 Mb)
PDF





Downloadable Citations